Biotech's average P/E ended the year at 18.4, down 24% from 3Q12 but up 11% from 4Q11. The 4Q drop was primarily due to a decline in the stock price of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and the removal of Vertex Pharmaceuticals Inc.